Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200.

Journal: Blood advances •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Bashir Q, Thall PF, Kawedia JD, et al. (2026). "Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200.". Blood advances. https://doi.org/10.1182/bloodadvances.2026020293